"I think it was super important to rectify the narrative around Alzheimer's which didn't have women in the narrative."@mariashriver, spoke to @mcgrathmag about why she's advocating for women's brain research. #ForbesOver50https://t.co/BS8AlWCAb8 https://t.co/ljOmBCL78i ...

"I think it was super important to rectify the narrative around Alzheimer's which didn't have women in the narrative."@mariashriver, spoke to @mcgrathmag about why she's advocating for women's brain research. #ForbesOver50https://t.co/BS8AlWCAb8 https://t.co/Dr7pscLwd0 ...

"I think it was super important to rectify the narrative around Alzheimer's which didn't have women in the narrative."@mariashriver, spoke to @mcgrathmag about why she's advocating for women's brain research. #ForbesOver50https://t.co/BS8AlWCAb8 https://t.co/dtZyoerPrO ...

When you got eyes on this new research, what struck you. >> Yeah, so for a long time, Morgan, we've known that there is a genetic risk that you can test for, a gene called the APO E4 gene. I'll just refer to it as the APO gene.It gives you a higher risk of Alzheimer's. And more and more people are getting that checked out. What we always have tried to figure out though is does a genetic risk automatically translate to a clinical risk.Can you have the gene and can you overcome the clinical possibility of dem ...

What lifestyle changes do you want people to be most aware of. >> One of the studies really just looked at something pretty straight up Morgan walking. So they just looked at people who they had to self-report it.They looked at thousands of adults over 10 years and they broke out the people into different risk groups. People that had that APOE4 gene mutation that I mentioned that gives you a higher risk and people who didn't. Here's what's really interesting.For people that had the gene, it really dramatica ...

FDA & HRT Treatment Overview - FDA is clarifying the use of hormone replacement therapy (HRT) for perimenopause and menopause, suggesting previous risk assessments may be overstated [1] - The central argument revolves around whether the benefits of HRT outweigh the risks, particularly concerning stroke, blood clots, dementia, and breast cancer [3][6][8] Risk Assessment & Black Box Warning - Current medication labels include a black box warning about increased risks of heart disease, heart attack, strokes, and breast cancer [2][5] - The FDA is considering removing the black box warning due to arguments that the benefits of HRT outweigh the risks [5][6] - A 2002 women's health initiative study, with an average participant age of 63, is being re-evaluated, as HRT is often prescribed to women in their late 40s and 50s [6] - The perceived risk of breast cancer from HRT is considered by some to be overblown [7] - Baseline risk of developing breast cancer is around 13% for women in the United States [3][4] Benefits of HRT - Potential benefits of HRT include reduced risk of dementia and Alzheimer's, prevention of bone loss, and alleviation of menopause symptoms like hot flashes, poor sleep, and brain fog [8] - Estrogen, a key component of HRT, aids neurotransmitter function, potentially lowering the likelihood of dementia and Alzheimer's [9][10]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]